

Why Indian pharma isn't scared of a 100% tariff (yet)
Last Tuesday, Trump announced 100% tariffs on generic medicines imported into the US. By Wednesday, Indian pharma stocks were already falling even though the tariff doesn't take effect for two years. Trump wants import companies to reshore their manufacturing to the US so that the country can secure life-saving…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Daybreak
See all episodes →
Why global betting giants are paying Indian data scouts to see games before bettors

Engineering profits are slipping and L&T Tech is going all in on AI

Complan says it makes kids grow 2X faster. FSSAI wants to see the proof
Similar episodes from other shows
More like Daybreak →
How can India’s pharma companies survive under Trump’s uncertainty?

What Trump's tariffs mean for India

A Pharmaceutical Executive on Trump’s Tariff Strategy

What Trump’s Latest Tariff Salvo at India Means
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.